Cholestatic Liver Diseases: Therapeutic Options and Perspectives: In Honour of Hans Popper's 100th Birthday

Front Cover
U. Leuschner, U. Broomé, A. Stiehl
Springer Science & Business Media, Jun 30, 2004 - Medical - 388 pages
0 Reviews
During the last decade, knowledge about cholestatic liver disease and concomitant diseases, such as ulcerative colitis, cholangio- and hepatocellular carcinoma, pancreas and colon cancer, has increased considerably. Studies on ursodeoxycholic acid treatment alone or in combination with immunosuppressive compounds and their positive effects on biliary liver disease as well as on so-called overlap syndromes or intestinal tumors are published in increasing numbers, and stimulate discussion on whether or not ursodeoxycholic acid is able to improve the general condition and/or life expectancy of patients. On the other hand, genetics, aetiological and pathogenetic aspects are still difficult to comprehend, but are the absolute prerequisite for the development of better treatment options.
This book is the proceedings of Falk Symposium No. 136 (Part I of the XII Falk Liver Week, held in Freiburg, Germany, on October 15-16, 2003), and contains stimulating, exciting and controversial papers on clinical and also basic research at the highest scientific level.
 

What people are saying - Write a review

We haven't found any reviews in the usual places.

Selected pages

Contents

Epidemiology of primary biliary cirrhosis
3
Genetic components of primary biliary cirrhosis
13
Infectious aetiology of primary biliary cirrhosis
27
Gender and primary biliary cirrhosis is microchimerism an aetiological factor?
37
HISTOLOGY AND IMMUNOLOGY OF PRIMARY BILIARY CIRRHOSIS AND AUTOIMMUNE CHOLESTATIC DISEASE
45
Histology of autoimmune cholestatic liver diseases
47
Mechanisms of biliary epithelial cell apoptosis in primary biliary cirrhosis
56
Role of autoantibodies and autoantigens in primary biliary cirrhosis
69
Incidence and prevalence of primary sclerosing cholangitis around the world
218
Small duct primary sclerosing cholangitis a separate disease?
225
Prognosis of untreated primary sclerosing cholangitis
231
PRIMARY SCLEROSING CHOLANGITIS AN AUTOIMMUNE DISEASE?
241
Is primary sclerosing cholangitis an autoimmune disease?
243
Autoimmune markers and their role in the pathogenesis of primary sclerosing cholangitis
247
The HLA system and other genetic markers in primary sclerosing cholangitis
257
Viruses protozoans bacteria and drugs as aetiological factors in primary sclerosing cholangitis
273

CLINICS OF PRIMARY BILIARY CIRRHOSIS
77
Clinical aspects and prognosis of primary biliary cirrhosis
79
Pathogenesis of pruritus and fatigue in cholestatic liver disease
94
Is osteoporosis a specific complication of primary biliary cirrhosis?
110
Diseases associated with primary biliary cirrhosis
117
OVERLAP SYNDROMES
123
Overlap syndromes outlier syndromes and changing diagnoses
125
The autoimmune hepatitishepatitis C overlap syndrome does it exist?
132
Histopathology of overlap syndromes in the liver
147
TREATMENT OF PRIMARY BILIARY CIRRHOSIS
159
Mechanisms of action of ursodeoxycholic acid in cholestasis
161
Primary biliary cirrhosis longterm therapy with ursodeoxycholic acid
171
Combination therapy of primary biliary cirrhosis and overlap syndromes
179
Management of pruritus fatigue and bone disease in patients with primary biliary cirrhosis
188
Liver transplantation rejection and disease recurrence
197
DIAGNOSIS EPIDEMIOLOGY AND PROGNOSIS OF PRIMARY SCLEROSING CHOLANGITIS
201
Primary sclerosing cholangitis diagnosis and differential diagnosis
203
PRIMARY SCLEROSING CHOLANGITIS AND ASSOCIATED DISEASES
281
Primary sclerosing cholangitis and inflammatory bowel disease when and how do they relate to each other?
283
Extrahepatic and extraintestinal manifestations of primary sclerosing cholangitis
289
Primary sclerosing cholangitis in paediatrics what is different?
293
TREATMENT OPTIONS IN PRIMARY SCLEROSING CHOLANGITIS
299
Ursodeoxycholic acid highdose monotherapy or combination therapy?
301
Endoscopic treatment of dominant stenoses in patients with primary sclerosing cholangitis
309
How should and how does antifibrotic therapy act in biliary fibrosis?
314
Ursodeoxycholic acid to prevent colon cancer in primary sclerosing cholangitis
323
MALIGNANCIES IN PRIMARY SCLEROSING CHOLANGITIS
333
Hepatocellular carcinoma cholangiocarcinoma colon and pancreatic carcinoma in patients with primary sclerosing cholangitis epidemiology and risk ...
335
Tumour markers and genetic markers in the diagnosis of bile duct carcinoma
345
Histology and brush cytology for diagnosis of bile duct carcinoma in primary sclerosing cholangitis
354
Primary sclerosing cholangitis indications for and recurrence after transplantation
364
Index
379
Copyright

Other editions - View all

Common terms and phrases

Bibliographic information